ArticleScientific reports2026
Multi-analytical and biological insights into Malcolmia grandiflora Kuntze.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The examination of natural resources represents a promising avenue for discovering bioactive natural products. The genus Malcolmia (Brassicaceae) has received minimal phytochemical investigation, despite the recognized pharmacological potential of Brassicaceae members. Herein, Malcolmia grandiflora Kuntze was investigated through phytochemical and biological examination of its n-hexane and defatted extracts utilizing GC-MS, LC-HRMS, and in vitro assays. The n-hexane extract exhibited potent cytotoxicity against colorectal and breast cancer cell lines, whereas the defatted extract displayed selective COX-2 inhibition. Evaluation of the antioxidant efficacy revealed moderate activity of the defatted extract outperforming that of the n-hexane extract in the ABTS and FRAP assays, while both extracts displayed weak activity in the DPPH assay. GC-MS analysis revealed 20 metabolites, mainly fatty acid derivatives, esters, and long-chain alcohols. LC-HRMS analysis unveiled diversified metabolic content dominated by flavonoids, sesquiterpenoids, and isothiocyanates. Molecular docking indicated moderate binding affinities of the n-hexane metabolites, the disparity noted between the n-hexane extract's cytotoxicity results and its metabolites' moderate binding affinities suggests the involvement of distinct mechanisms of action. In contrast, docking results underscore flavonoids as promising Cyclin dependent kinases (CDKs) targeted anticancer leads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.